NCT01668225

Brief Summary

Recently, scientists look into G-CSF (Granulocyte - Colony Stimulatin Factor). The use of this molecule is increasing in reproduction pathology. High level of follicular and blood G-CSF on the day of oocyte retrieval could correlate with higher pregnancy and implantation rates.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
152

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 19, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 20, 2012

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
Last Updated

September 10, 2022

Status Verified

September 1, 2022

Enrollment Period

4.8 years

First QC Date

June 19, 2012

Last Update Submit

September 8, 2022

Conditions

Infertility

Outcome Measures

Primary Outcomes (1)

  • Serum and / or follicular minimum level of G-CSF predictive of pregnancy

    6 months

Study Arms (1)

G-CSF FIV nat

Patient following a natural In Vitro Fecondation cycle

Procedure: Blood test

Interventions

Blood testPROCEDURE

Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day. Taking the follicular fluid during the oocyte collection day

G-CSF FIV nat

Eligibility Criteria

Age18 Years - 43 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Women with a natural cycle of an In Vitro Fecondation

You may qualify if:

  • Women between 18 and 43 years old
  • Women natural In Vitro Fecondation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ovo Fertilité

Montreal, Quebec, H4P 2S4, Canada

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum sample Follicular fluid

MeSH Terms

Conditions

Infertility

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • Jacques Kadoch, MD

    Clinique Ovo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2012

First Posted

August 20, 2012

Study Start

March 1, 2012

Primary Completion

January 1, 2017

Study Completion

January 1, 2017

Last Updated

September 10, 2022

Record last verified: 2022-09

Locations

CA(1)